NYSE:PFE

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Tuesday, March 5, 2024

Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024 at 8:00 a.m. Eastern Daylight Time.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024 at 8:00 a.m. Eastern Daylight Time.
  • To listen to the webcast, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults

Retrieved on: 
Thursday, February 29, 2024

Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial ( NCT05035212 ) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial ( NCT05035212 ) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease).
  • Vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD), defined by three or more symptoms, after disease surveillance in season two was 77.8% (95.0% CI: 51.4, 91.1); vaccine efficacy following season one was 88.9% (95.0% CI: 53.6%, 98.7%)1, which demonstrates durable efficacy after two seasons.
  • Consistent vaccine efficacy was demonstrated for both RSV A and RSV B after season two with vaccine efficacy against each subtype of ≥80% for LRTD with three or more symptoms.
  • No new adverse events were reported through the second RSV season beyond what was reported by subjects in the clinical trial during the first season.

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

Retrieved on: 
Thursday, February 29, 2024

A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .

Key Points: 
  • A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .
  • “With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • Pfizer’s Oncology portfolio is focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.
  • Please read full Prescribing Information , including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Monday, February 26, 2024

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 11:10 a.m. Eastern Standard Time.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 11:10 a.m. Eastern Standard Time.
  • To listen to the webcast, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Monday, February 19, 2024

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
  • “For the 2.6 million people in Europe living with UC, the unpredictable physical, mental, and emotional impacts of the condition can be debilitating.
  • This authorization follows the recommendation for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2023.
  • Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of VELSIPITY.

Thinking about trading options or stock in Advanced Micro Devices, Pfizer, Samsara, New York Community Bancorp, or Walmart?

Retrieved on: 
Friday, March 8, 2024

NEW YORK, March 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, PFE, IOT, NYCB, and WMT.

Key Points: 
  • NEW YORK, March 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, PFE, IOT, NYCB, and WMT.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report – Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day

Retrieved on: 
Thursday, February 15, 2024

Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint.
  • During the event, Pfizer Oncology leadership will provide details on the new combined Pfizer Oncology Division, including its strategic approach, robust portfolio, industry-leading R&D capabilities and potential for growth through 2030 and beyond.
  • To access the live webcast and presentation slides, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.

Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

Retrieved on: 
Thursday, February 15, 2024

A recent report from Allied Market Research projected that the Global Fibromyalgia Treatment Market size, which was valued at $3.1 billion in 2022, is estimated to reach $4.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2032.

Key Points: 
  • A recent report from Allied Market Research projected that the Global Fibromyalgia Treatment Market size, which was valued at $3.1 billion in 2022, is estimated to reach $4.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2032.
  • The report said: “The rising incidence and recognition of fibromyalgia as a chronic pain condition have driven the demand for effective treatment options.
  • Fibromyalgia is more commonly diagnosed in older adults, and as the global population ages, there is a growing prevalence of this condition.
  • Allied Market Research continued: “As more individuals are identified with fibromyalgia, there is a greater demand for appropriate treatment options.

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

Retrieved on: 
Wednesday, February 14, 2024

While some of them are malignant (cancer), others are benign (not cancer) or precancerous (may develop into cancer).

Key Points: 
  • While some of them are malignant (cancer), others are benign (not cancer) or precancerous (may develop into cancer).
  • According to the World Health Organization (WHO), an increase of roughly 70% in anal cancer cases is projected globally over the Anal Cancer Market Analysis period (2030).
  • The Americas are likely to lead the anal cancer market because of the increased prevalence of anal cancer.
  • Europe is predicted to represent the second-largest share of the anal cancer market because of the increased prevalence of anal cancer and the presence of significant market participants.

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

Retrieved on: 
Wednesday, February 14, 2024

“We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.

Key Points: 
  • “We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • “We believe there is great potential for this combination treatment, based on the encouraging initial clinical trial data for vepdegestrant and Pfizer’s deep expertise in developing treatments for breast cancer.”
    The Phase 1b/2 clinical trial has two parts.
  • In Phase 1b, escalating doses of samuraciclib and vepdegestrant will be tested to determine appropriate doses of each therapy to be used in combination.
  • This clinical trial evaluating the novel combination of samuraciclib and vepdegestrant is being conducted as part of the TACTIVE-U study in collaboration with Arvinas and Pfizer under a clinical trial collaboration and supply agreement.